The production base of Zheng Da Tianqing Pharmaceutical Group Co., Ltd. is busy. A master who has worked in Tianqing, Zheng Da for more than 20 years said that a few years ago, the workshop had to rest for at least one or two months every year to carry out equipment maintenance. Sales determine production, and production is not "easy" in sales;
In 2007-2008, the sales of Zheng Da Tianqing achieved a growth rate of more than 50%, and liver medicine products accounted for 18% of the national hospital hepatopathy drug market. In 2009, Zheng Da Tianqing won the heavy honor of "National May Day Labor Award" with its outstanding contribution to serving local economy, independent innovation and harmonious development.
Zheng Da Tianqing's investment in scientific and technological innovation has reached 8% of sales revenue. At present, the number of patent applications exceeds 100, and the sales of products with independent intellectual property rights account for 60% of the total sales. Zheng Da Tianqing suffered from the lack of independent innovation ability at the beginning of its business. In 1980s, Dongfeng Pharmaceutical Factory, the predecessor of Tianqing Pharmaceutical in Zheng Da, Jiangsu Province, followed closely and started the Norfloxacin project. This was a promising and profitable project at that time. Soon, the news came that the prospect of norfloxacin project was worrying. It is not that the demand market for this drug has changed, but that everyone is optimistic about this "cake". You are doing it, others are doing it, and the pharmaceutical companies launched are blooming everywhere. It is said that there were more than 1000 pharmaceutical companies producing norfloxacin in China at that time. The management decided to dismount the project, which was more difficult than getting on the horse, but the emergency braking minimized the loss of Dongfeng Pharmaceutical Factory. "Going to Maicheng" makes people realize that they must find their own way.
At that time, there was a drug "Qianglixin" in Japan, which could improve human immunity and had a remarkable effect on treating hepatitis. Through various channels, I learned that an R&D institution in China is also developing this drug. Dongfeng pharmaceutical factory finally bought this technology at a high price. Later, this drug was registered as Dongfeng brand "Li Qiangning" and became the "fist product" of the factory, which was a great success. The awakened sense of innovation is out of control, and the investment in innovation has increased year after year, reaching more than 8% of sales revenue. Based on continuous innovation investment, Zheng Da Tianqing has continuously introduced eight new drugs for treating liver diseases in the past 20 years, and "Li Qiangning" is still an eye-catching coordinate.
In 2008, magnesium isoglycyrrhizinate, a new drug patented exclusively by Zheng Da Tianqing, won the 10th China Patent Award and became one of the few China patent gold medals in China pharmaceutical industry. Magnesium isoglycyrrhizinate is the first magnesium glycyrrhizinate product with high purity α-glycyrrhizic acid in the world, which was successfully developed by Zheng Da Tianqing Pharmaceutical Co., Ltd. with advanced technology for 8 years. In the field of glycyrrhizic acid preparation research and development, Zheng Da Tianqing has reached the first place in China and the leading position in the world.
In recent years, the proportion of R&D investment in the sales revenue of Zheng Da Tianqing has been increasing, and the current budget investment has reached 8% of the sales revenue. By the end of 2008, Zheng Da Tianqing had applied for patents 1 16, including 96 invention patents and 44 authorized patents. In 2008, the sales revenue of patented products accounted for more than 50% of the total sales revenue. In 2009, the R&D investment budget was 654.38+0.9 billion yuan.
At present, Zheng Da Tianqing has its own pharmaceutical research institute, and the annual R&D investment exceeds 654.38 billion yuan. The R&D plan has been scheduled to 2065.438+05, and the products have formed a benign development cycle of "production generation, reserve generation, research generation and conception generation".
Because Zheng Da Tianqing has been focusing on the research and development of liver health care drugs and has strong technical advantages, the company's R&D center was recognized as "Jiangsu New Liver Disease Drug Engineering Technology Research Center" by the Science and Technology Department of Jiangsu Province.
At the beginning of 2009, Zheng Da Tianqing Drug Research Institute was established; In April, the foundation stone was laid for Zheng Da Tianqing Preparation New District with a total investment of 720 million yuan, and it was put into use on 20 12. In August, Zheng Da Tianqing API Base passed GMP certification and was successfully put into production.
Zheng Da Tianqing Pharmaceutical Co., Ltd. is striving to increase its production capacity, transform its production workshop, and build a new API base and a new preparation area.
20 13 was officially renamed as "Zheng Da Tianqing Pharmaceutical Group Co., Ltd.".